Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Motif Bio
Biotech
Liver toxicity concerns spike Motif Bio’s iclaprim filing
Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.
Phil Taylor
Feb 14, 2019 10:30am
Chutes and Ladders—Atara hires ex-Genentech SVP to lead R&D
May 11, 2018 9:46am
Motif Bio phase 3 hits endpoint, teeing up date with FDA
Oct 4, 2017 9:40am
Motif Bio antibiotic hits endpoint in skin infection phase 3
Apr 18, 2017 3:31am
Motif Bio prices U.S. IPO, EU offering to save antibiotic PhIII
Nov 18, 2016 3:02am
Motif Bio seeks last-gasp financing as cash crunch hits
Oct 31, 2016 9:39am
